Breath- and blood-based molecular assessment for gastroesophageal cancer

S. Vanstraelen , F. Van Herpe , J. Dekervel , P. Nafteux
{"title":"Breath- and blood-based molecular assessment for gastroesophageal cancer","authors":"S. Vanstraelen ,&nbsp;F. Van Herpe ,&nbsp;J. Dekervel ,&nbsp;P. Nafteux","doi":"10.1016/j.esmogo.2025.100132","DOIUrl":null,"url":null,"abstract":"<div><div>Gastroesophageal cancer remains a significant health care problem characterized by diagnosis at advanced stages, rendering a significant proportion of patients ineligible for curative treatment. Conversely, early diagnosis and treatment of gastroesophageal cancer demonstrates markedly improved outcomes, with 5-year overall survival rates ranging from 83% to 96%. To date, gastroesophageal cancer surveillance primarily focuses on patients with Barrett’s esophagus, relying on invasive upper endoscopy. However, despite its high specificity, upper endoscopy demonstrates a suboptimal cancer yield and moderate missed rates, compromising its cost-effectiveness for screening in the general population. Moreover, screening strategies for gastroesophageal cancer are still lacking, in part owing to the invasiveness of current diagnostic methods.</div><div>To overcome these challenges, innovative minimally invasive technologies have emerged, including metabolomics of exhaled breath, and detection of circulating tumor DNA or proteomics in blood. Promising results from phase I diagnostic trials emphasize the potential of these approaches to advance early detection and monitoring of gastroesophageal cancer. As these methods further refine and consistently demonstrate adequate sensitivity and specificity, they are poised to challenge existing diagnostic modalities. This progress may prompt reconsideration of current one-size-fits-all paradigms, facilitating the evolution toward a patient-tailored management of gastroesophageal cancer.</div><div>In this article, we review the current minimally invasive breath- and blood-based diagnostic approaches for gastroesophageal cancer, elucidating the underlying biologic basis of identifiable biomarkers. As these approaches will become an integral part of future diagnostic paradigms, understanding the operational mechanisms, strengths, and limitations of these approaches is crucial for optimizing their implementation and interpretability in clinical practice.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100132"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Gastroesophageal cancer remains a significant health care problem characterized by diagnosis at advanced stages, rendering a significant proportion of patients ineligible for curative treatment. Conversely, early diagnosis and treatment of gastroesophageal cancer demonstrates markedly improved outcomes, with 5-year overall survival rates ranging from 83% to 96%. To date, gastroesophageal cancer surveillance primarily focuses on patients with Barrett’s esophagus, relying on invasive upper endoscopy. However, despite its high specificity, upper endoscopy demonstrates a suboptimal cancer yield and moderate missed rates, compromising its cost-effectiveness for screening in the general population. Moreover, screening strategies for gastroesophageal cancer are still lacking, in part owing to the invasiveness of current diagnostic methods.
To overcome these challenges, innovative minimally invasive technologies have emerged, including metabolomics of exhaled breath, and detection of circulating tumor DNA or proteomics in blood. Promising results from phase I diagnostic trials emphasize the potential of these approaches to advance early detection and monitoring of gastroesophageal cancer. As these methods further refine and consistently demonstrate adequate sensitivity and specificity, they are poised to challenge existing diagnostic modalities. This progress may prompt reconsideration of current one-size-fits-all paradigms, facilitating the evolution toward a patient-tailored management of gastroesophageal cancer.
In this article, we review the current minimally invasive breath- and blood-based diagnostic approaches for gastroesophageal cancer, elucidating the underlying biologic basis of identifiable biomarkers. As these approaches will become an integral part of future diagnostic paradigms, understanding the operational mechanisms, strengths, and limitations of these approaches is crucial for optimizing their implementation and interpretability in clinical practice.
胃食管癌的呼吸和血液分子评估
胃食管癌仍然是一个重要的卫生保健问题,其特点是晚期诊断,使相当大比例的患者没有资格获得治愈性治疗。相反,早期诊断和治疗胃食管癌的预后明显改善,5年总生存率从83%到96%不等。迄今为止,胃食管癌的监测主要集中在Barrett食管患者,依靠侵入性上内镜检查。然而,尽管其具有高特异性,但上端内窥镜检查显示出次优的癌症发生率和中等的漏诊率,这损害了其在普通人群中筛查的成本效益。此外,胃食管癌的筛查策略仍然缺乏,部分原因是当前诊断方法的侵入性。为了克服这些挑战,创新的微创技术已经出现,包括呼气代谢组学,血液循环肿瘤DNA或蛋白质组学检测。来自I期诊断试验的令人鼓舞的结果强调了这些方法在推进胃食管癌早期检测和监测方面的潜力。随着这些方法的进一步完善和持续表现出足够的敏感性和特异性,它们准备挑战现有的诊断模式。这一进展可能会促使人们重新考虑目前的一刀切模式,促进胃食管癌患者量身定制管理的发展。在本文中,我们回顾了目前基于呼吸和血液的微创胃食管癌诊断方法,阐明了可识别生物标志物的潜在生物学基础。由于这些方法将成为未来诊断范式的组成部分,因此了解这些方法的操作机制、优势和局限性对于优化其在临床实践中的实施和可解释性至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信